6533b824fe1ef96bd1281614

RESEARCH PRODUCT

Efficacy and safety of direct-acting antiviral therapy in previous hard-to-treat patients with recurrent hepatitis C virus infection after liver transplantation: a real-world cohort.

Daniel GrimmJens MittlerMichael HeiseMaria Hoppe-lotichiusJohanna VollmarPeter R. GalleTim ZimmermannHauke LangSebastian BernuthF. Darstein

subject

Liver CirrhosisMaleHepacivirusmedicine.medical_treatmentPharmaceutical ScienceHepacivirusLiver transplantationGastroenterologyCohort Studieschemistry.chemical_compound0302 clinical medicineRecurrenceDrug DiscoveryMedicine030212 general & internal medicineOriginal Researchbiologyliver transplantationvirus diseasesMiddle AgedTreatment OutcomeCohortHCV030211 gastroenterology & hepatologyDrug Therapy CombinationFemalesustained virological responseCohort studymedicine.medical_specialtySVRAntiviral Agentsreinfection03 medical and health sciencesInternal medicineHumansSurvival analysisAgedRetrospective StudiesDAAPharmacologyDrug Design Development and Therapybusiness.industryRibavirinRetrospective cohort studyHepatitis C Chronicbiology.organism_classificationVirologySurvival Analysisdigestive system diseasesDiscontinuationchemistrybusiness

description

Sebastian Bernuth,1 Daniel Grimm,1 Johanna Vollmar,1 Felix Darstein,1 Jens Mittler,2 Michael Heise,2 Maria Hoppe-Lotichius,2 Peter R Galle,1 Hauke Lang,2 Tim Zimmermann1 1First Department of Internal Medicine, Transplant Hepatology, 2General-, Abdominal- and Transplant- Surgery, University Medical Center, Johannes Gutenberg University, Mainz, Germany Background: Recurrent hepatitis C virus (HCV) infection after liver transplantation (LT) has been a frequent and relevant problem in the past two decades. This analysis evaluated the efficacy and safety of new interferon (IFN)-free direct-acting antiviral (DAA) therapies in a large real-world cohort of HCV patients after LT.Methods: We retrospectively analyzed a cohort of 157 patients infected with HCV who underwent deceased donor LT between 1997 and 2014. Patient survival, outcome, and side effects of antiviral therapy were assessed.Results: Survival with recurrent HCV genotype 1 (GT1) infection was inferior to other HCV GTs (P=0.01). The overall sustained virological response (SVR) rate with new DAA therapy was 94.6% (n=37). Patients with both GT1 and other GTs reached SVR rates >90%. We noticed a few side effects, mainly caused by ribavirin, and only one discontinuation in DAA-treated patients.Conclusion: DAA therapy was effective and safe in previous hard-to-treat patients after LT in this real-world cohort. Keywords: HCV, DAA, liver transplantation, reinfection, sustained virological response, SVR

yearjournalcountryeditionlanguage
2017-07-27Drug design, development and therapy
10.2147/dddt.s139837https://pubmed.ncbi.nlm.nih.gov/28744104